Takeaways From the Annual J.P. Morgan Healthcare Conference
The annual J.P. Morgan Healthcare Conference often sets the tone for the sector in the year ahead, and this year the contrast with 2025 was striking. After a period defined by policy uncertainty—particularly across pharma and biotech—the mood was materially more upbeat.
With much of the policy overhang now resolved, management teams appeared firmly on offense. Large-cap pharmaceutical companies facing upcoming patent expiries openly discussed the need for growth-driving transactions, including the possibility of large-scale acquisitions exceeding $15 billion.
Meanwhile, AI efforts across the sector are accelerating in scope and seriousness, increasingly viewed as long-term investments in efficiency, speed, and competitive advantage.
While deal announcements themselves remained limited, strategic appetite was unmistakable. Conversations at the conference consistently pointed to interest across oncology, cardiometabolic disease, and growth-oriented medical devices.
Companies such as Revolution Medicines and Abivax were frequently cited as potential acquisition candidates, though outcomes remain uncertain. More broadly, commentary reinforced sustained interest in areas like oncology and chronic disease, where innovation remains critical and demand durable.
Structurally, many large biopharma companies face meaningful revenue exposure to generic erosion which is particularly acute starting in 2026 and beyond. Against that backdrop, external innovation remains an important lever. Improved policy clarity—alongside continued signals from the FDA supporting biotech innovation—helps explain the level of strategic engagement evident at the conference.
Outside therapeutics, companies also demonstrated a willingness to deploy capital to enhance growth profiles, exemplified by Boston Scientific’s announced acquisition of vascular device company Penumbra.
Investor attention increasingly centered on specific, near-term catalysts, with three standing out:
AI was a consistent theme throughout the conference—not as a near-term valuation driver, but as a longer-term force reshaping healthcare and life sciences.
With healthcare spending approaching 20% of U.S. GDP, efficiency gains remain a powerful lever. At the conference, Thermo Fisher Scientific highlighted its AI collaboration with NVIDIA, aimed at improving efficiency and scale across life sciences workflows and reinforcing its competitive advantages.
Elsewhere, companies such as Eli Lilly emphasized AI’s potential to shorten development timelines and accelerate time to clinic, while Intuitive Surgical showcased efforts to integrate AI across its robotic platforms to enhance surgical outcomes.
While system-wide benefits will take time to materialize, these initiatives reflect a broader shift toward using AI to transform healthcare delivery itself—an important third dimension of AI adoption that could ultimately make healthcare a compelling and differentiated AI investment opportunity.
Healthcare enters 2026 with improving fundamentals, clearer policy visibility, and multiple credible catalysts across therapeutics, devices, and technology. Despite this progress, valuations across much of the sector remain attractive relative to history, even as innovation momentum rebuilds.
For investors, this combination—early-cycle recovery dynamics paired with long-duration secular growth—creates an opportunity to re-engage with healthcare at a moment when sentiment is improving, capital deployment is accelerating, and expectations remain measured.
For more of our research and recent insights on healthcare and more, view and subscribe to our insights.